New insights into the role of the complement pathway in allergy and asthma

  • Marsha Wills-Karp
  • Joerg Koehl


Despite extensive inquiry, the mechanisms underlying the pathophysiology of allergic diseases remain unknown. Recently, there has been a resurgence of interest in the role of the innate immune mediators of the complement pathway in asthma pathogenesis, particularly the anaphylatoxins (C3a, C5a). The emerging paradigm is that C3a production at the airway surface serves as a common pathway for the induction of airway hyperresponsiveness to a variety of asthma triggers (ie, allergens, viral infections, particulate matter, ozone, smoke), whereas C5/C5a plays a dual immunoregulatory role by protecting against Th2-mediated immune responses during initiation of responses and a proinflammatory role once immune responses are established. Support for a causal role for altered anaphylatoxin production in human disease comes from reports of exaggerated complement production in the lungs of asthmatics as well as the association of asthma with polymorphisms in C3/C3aR genes. Herein, we explore our current understanding of the role of complement activation in asthma pathogenesis and highlight the potential of targeting complement pathways for therapeutic drug development.


Asthma Respiratory Syncytial Virus Complement Activation Allergy Clin Immunol Allergic Asthma 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References and Recommended Reading

  1. 1.
    Wills-Karp M: Immunologic basis of antigen-induced airway hyperresponsiveness. Annu Rev Immunol 1999, 17:255–281.PubMedCrossRefGoogle Scholar
  2. 2.
    Fearon DT: The complement system and adaptive immunity. Semin Immunol 1998, 10:355–361.PubMedCrossRefGoogle Scholar
  3. 3.
    Prodinger WM, Würzner R, Erdei A, Dierich MP: Complement. In Fundamental Immunology, edn 4. Edited by Paul W. Philadelphia: Lippincott-Raven Press; 1998:967–996.Google Scholar
  4. 4.
    Stimler-Gerard NP: Immunopharmacology of anaphylatoxininduced bronchoconstrictor responses. Complement 1986, 3:137–151.PubMedGoogle Scholar
  5. 5.
    Gerard C, Gerard NP: C5A anaphylatoxin and its seven transmembrane-segment receptor. Annu Rev Immunol 1994, 12:775–808.PubMedCrossRefGoogle Scholar
  6. 6.
    Ames RS, Li Y, Sarau HM, et al.: Molecular cloning and characterization of the human anaphylatoxin C3a receptor. J Biol Chem 1996, 271:20231–20234.PubMedCrossRefGoogle Scholar
  7. 7.
    Kirchhoff K, Weinmann O, Zwirner J, et al.: Detection of anaphylatoxin receptors on CD83+ dendritic cells derived from human skin. Immunology 2001, 103:210–217.PubMedCrossRefGoogle Scholar
  8. 8.
    Nataf S, Davoust N, Ames RS, Barum SR: Human T cells express the C5a receptor and are chemoattracted to C5a. J Immunol 1999, 62:4018–4023.Google Scholar
  9. 9.
    Werfel T, Kirchhoff K, Wittmann M: Activated human T lymphocytes express a functional C3a receptor. J Immunol 2000, 165:6599–6605.PubMedGoogle Scholar
  10. 10.
    Drouin SM, Kildsgaard J, Haviland J, et al.: Expression of the complement anaphylatoxin C3a and C5a receptors on bronchial epithelial and smooth muscle cells in models of sepsis and asthma. J Immunol 2001, 166:2025–2032.PubMedGoogle Scholar
  11. 11.
    Fischer MB, Ma M, Hsu NC, Carroll MC: Local synthesis of C3 within the splenic lymphoid compartment can reconstitute the impaired immune response in C3-deficient mice. J Immunol 1998, 160:2619–2625.PubMedGoogle Scholar
  12. 12.
    Schwartz LB, Kawahara MS, Hugli TE, et al.: Generation of C3a anaphylatoxin from human C3 by human mast cell tryptase. J Immunol 1983, 130:1891–1895.PubMedGoogle Scholar
  13. 13.
    Nagata S, Glovsky MM: Activation of human serum complement with allergens. I. Generation of C3a, C4a, C5a and induction of human neutrophil aggregation. J Allergy Clin Immunol 1987, 80:24–32.PubMedGoogle Scholar
  14. 14.
    Castro FFM, Schmitz-Schumann M, Rother U, Kirschfink M:Complement activation by house dust: reduced reactivity of serum complement in patients with bronchial asthma. Int Arch Allergy Appl Immunol 1991, 96:305–310.PubMedGoogle Scholar
  15. 15.
    Mauro K, Akaike T, Ono T, et al.: Generation of anaphylatoxins through proteolytic processing of C3 and C5 by house dust mite protease. J Allergy Clin Immunol 1997, 100:253–260.CrossRefGoogle Scholar
  16. 16.
    Khirwadkar K, Zilow G, Oppermann M, et al.: Interleukin-4 augments production of the third complement component by the alveolar epithelial cell line A549. Int Arch Allergy Immunol 1993, 100:35–41.PubMedCrossRefGoogle Scholar
  17. 17.
    Walters DM, Breysse PN, Schofield B, Wills-Karp M: Complement factor 3 mediates particulate matter-induced airway hyperresponsiveness. Am J Respir Cell Mol Biol 2002, 27:413–418.PubMedGoogle Scholar
  18. 18.
    Kanemitsu H, Nagasawa S, Sagai M, Mori Y: Complement activation by diesel exhaust particles (DEP). Biol Pharm Bull 1998, 21:129–132.PubMedGoogle Scholar
  19. 19.
    Park J-W, Taube C, Joetham A, et al.: Complement activation is critical to airway hyperresponsiveness after acute ozone exposure. Am J Respir Crit Care Med 2004, 169:726–732.PubMedCrossRefGoogle Scholar
  20. 20.
    Strunk RC, Eidlen DM, Mason RJ: Pulmonary alveolar type II epithelial cells synthesize and secrete proteins of the classical and alternative complement pathways. J Clin Invest 1988, 81:1419–1426.PubMedCrossRefGoogle Scholar
  21. 21.
    Tanhehco EJ, Yasojima K, McGeer PL, et al.: Free radicals upregulate complement expression in rabbit isolated heart. Am J Physiol Circ Physiol 2002, 279:H195-H201.Google Scholar
  22. 22.
    Devlin RB, McDonnell WF, Becker S, et al.: Time-dependent changes of inflammatory mediators in the lungs of humans exposed to 0.4 ppm ozone for 2 hr: a comparison of mediators found in bronchoalveolar lavage fluid 1 and 18 hr after exposure. Toxicol Appl Pharmacol 1996, 138:176–185.PubMedCrossRefGoogle Scholar
  23. 23.
    Robbins RA, Nelson XX, Grossman GL, et al.: Complement activation by cigarette smoke. Am J Physiol 1991, 260(4Pt1):L254–259.PubMedGoogle Scholar
  24. 24.
    Kew RR, Ghebrehiwet B, Janoff A: Characterization of the third component of complement (C3) after activation by cigarette smoke. Clin Immunol Immunopathol 1987, 44:248–258.PubMedCrossRefGoogle Scholar
  25. 25.
    Shima M, Adachi M: Effects of environmental tobacco smoke on serum levels of acute phase proteins in schoolchildren. Prev Med 1996, 25:617–624.PubMedCrossRefGoogle Scholar
  26. 26.
    Humbles AA, Lu B, Nilsson CA: A role for the C3a anaphylatoxin receptor in the effector phase of asthma. Nature 2000, 406:998–1001. This was the first study to describe a role for C3a in allergen-induced airway hyperresponsiveness.PubMedCrossRefGoogle Scholar
  27. 27.
    Bautsch W, Hoymann HG, Zhang Q, et al.: Cutting edge: guinea pigs with a natural C3a-receptor defect exhibit decreased bronchoconstriction in allergic airway disease: evidence for an involvement of the C3a anaphylatoxin in the pathogenesis of asthma. J Immunol 2001, 165:5401–5405.Google Scholar
  28. 28.
    Drouin SM, Corry DB, Kildsgaard J, Wetsel RA: Cutting edge: the absence of C3 demonstrates a role for complement in Th2 effector functions in a murine model of pulmonary allergy. J Immunol 2001, 167:4141–4145.PubMedGoogle Scholar
  29. 29.
    Drouin SM, Corry DB, Hollman TJ: Absence of the complement anaphylatoxin C3a receptor suppresses Th2 effector functions in a murine model of pulmonary allergy. J Immunol 2002, 169:5926–5933. This excellent paper identifies a role for C3a in promoting Th2-mediated immune responses in the lung.PubMedGoogle Scholar
  30. 30.
    Taube C, Rha Y-H, Takeda K, et al.: Inhibition of complement activation decreases allergic airway inflammation and hyperresponsiveness. Am J Respir Crit Care Med 2003, 168:1333–1341.PubMedCrossRefGoogle Scholar
  31. 31.
    Polack FP, Teng MN, Collins PI, et al.: A role for immune complexes in enhanced respiratory syncytial virus disease. J Exp Med 2002, 196:859–865.PubMedCrossRefGoogle Scholar
  32. 32.
    Kawamoto S, Yalcindag A, Laouini D, et al.: The anaphylatoxin C3a downregulates the Th2 response to epicutaneously introduced antigen. J Clin Invest 2004, 114:399–407.PubMedCrossRefGoogle Scholar
  33. 33.
    Baelder R, Fuchs B, Bautsch W, et al.: Pharmacological targeting of anaphylatoxin receptors during the effector phase of allergic asthma suppresses airway hyperresponsiveness and airway inflammation. J Immunol 2005, 174:783–789. This is an excellent study designed to define the role of C3a and C5a during the effector phase of the allergic response.PubMedGoogle Scholar
  34. 34.
    Mathieu M-C, Sawyer N, Greig GM,et al.: The C3a receptor antagonists SB 290157 has agonist activity. Immunology Letters 2005, In press.Google Scholar
  35. 35.
    Woolhiser MR, Brockow K, Metcalfe DD: Activation of human mast cells by aggregated IgG through FcgammaRI:additive effects of C3a. Clin Immunol 2004, 110:172–180.PubMedCrossRefGoogle Scholar
  36. 36.
    Stimler NP, Bloor CM, Hugli TE: C3a-induced contraction of guinea pig lung parenchyma: role of cyclooxygenase metabolites. Immunopharmacology 1983, 5:251–257.PubMedCrossRefGoogle Scholar
  37. 37.
    Hawlisch H, Wills-Karp M, Karp CL, Kohl J: The anaphylatoxins bridge innate and adaptive immune responses in allergic asthma. Mol Immunol 2004, 41:123–131.PubMedCrossRefGoogle Scholar
  38. 38.
    Karp CL, Grupe A, Schadt E, et al.: Identification of complement factor 5 as a susceptibility locus for experimental allergic asthma. Nature Immunol 2000, 1:221–226. This is an interesting study that identified C5 as a susceptibility gene for experimental asthma and provided support for the postulate that C5a provides protection against Th2-mediated immune responses via induction of IL-12.CrossRefGoogle Scholar
  39. 39.
    Wetsel RA, Fleischer DT, Haviland DL: Deficiency of the murine fifth complement component (C5): a 2-base pair gene deletion in a 5’-exon. J Biol Chem 1990, 265:2435–2440.PubMedGoogle Scholar
  40. 40.
    Abe M, Shibata K, Akatsu H, et al.: Contribution of anaphylatoxin C5a to late airway responses after repeated exposure of antigen to allergic rats. J Immunol 2001, 167:4651–4660.PubMedGoogle Scholar
  41. 41.
    Kawikova I, Paliwal V, Szczepanik M, et al.: Airway hyperreactivity mediated by B-1 cell immunoglobulin M antibody generating complement component C5a at 1 day post-immunization in a murine model of non-atopic asthma. Immunology 2004, 113:234–245.PubMedCrossRefGoogle Scholar
  42. 42.
    Gervais F, Stevenson M, Skamene E: Genetic control of resistance to Listeria monocytogenes: regulation of leukocyte inflammatory responses by the Hc locus. J Immunol 1984, 132:2078–2083.PubMedGoogle Scholar
  43. 43.
    Banda NK, Kraus D, Vondracek A, et al.: Mechanisms of effects of complement inhibition in murine collagen-induced arthritis. Arthritis Rheum 2002, 46:3065–3075.PubMedCrossRefGoogle Scholar
  44. 44.
    Karp CL, Wysocka M, Wahl LM, et al.: Mechanism of suppression of cell-mediated immunity by measles virus. Science 1996, 273:228–231.PubMedCrossRefGoogle Scholar
  45. 45.
    Gavett SH, O’Hearn DJ, Li X, et al.: Interleukin 12 inhibits antigen-induced airway hyperresponsiveness, inflammation, and Th2 cytokine expression in mice. J Exp Med 1995, 182:1527–1536.PubMedCrossRefGoogle Scholar
  46. 46.
    Keane-Myers A, Wysocka M, Trinchieri G, Wills-Karp M:Resistance to antigen-induced airway hyperresponsiveness requires endogenous production of IL-12. J Immunol 1998, 161:919–926.PubMedGoogle Scholar
  47. 47.
    de Heer HJ, Hammad H, Souillie T, et al.: Essential role of lung plasmacytoid dendritic cells in preventing asthmatic reactions to harmless inhaled antigens. J Exp Med 2004, 200:89–98.PubMedCrossRefGoogle Scholar
  48. 48.
    Krug N, Tschernig T, Erpenbeck VJ, et al.: Complement factors C3a and C5a are increased in bronchoalveolar lavage fluid after segmental allergen provocation in subjects with asthma. Am J Respir Crit Care Med 2001, 164:1841–1843.PubMedGoogle Scholar
  49. 49.
    Charlot C, Bowser C, Castro M, et al.: Inverse relationship of plasma C5a levels to allergic disease activity in pediatric but not adult populations. J Allergy Clin Immunol 2005, 115:S70.CrossRefGoogle Scholar
  50. 50.
    Nakano Y, Morita S, Kawamoto A, et al.: Elevated complement C3a in plasma from patients with severe acute asthma. J Allergy Clin Immunol 2003, 112:525–530.PubMedCrossRefGoogle Scholar
  51. 51.
    Wjst M, Fischer G, Immervoll T, et al.: A genome-wide search for linkage to asthma. German Asthma Genetics Group Genomics 1999, 58:1–8.Google Scholar
  52. 52.
    A genome-wide search for asthma susceptibility loci in ethnically diverse populations. The Collaborative Study on the Genetics of Asthma (CSGA). Nat Genet 1997, 15:389-392.Google Scholar
  53. 53.
    Hasegawa K, Tamari M, Shao C, et al.: Variations in the C3, C3a receptor, and C5 genes affect susceptibility to bronchial asthma. Hum Gene 2004, 115:295–301.Google Scholar

Copyright information

© Current Science Inc 2005

Authors and Affiliations

  • Marsha Wills-Karp
    • 1
  • Joerg Koehl
    • 1
  1. 1.Division of ImmunobiologyChildren’s Hospital Medical CenterCincinnatiUSA

Personalised recommendations